Trial Profile
Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque Injection 320 mgI/mL) on Renal Function in Adults With Chronic Kidney Disease (CKD) Stage III or Stage IV Who Have Undergone Endovascular Aneurysm Repair (EVAR)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Iodixanol (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors GE Healthcare
- 03 Apr 2022 This trial has been completed in Hungary (End Date: 19 Oct 2018), according to European Clinical Trials Database record.
- 28 Feb 2019 This trial has been discontinued in Netherlands, according to European Clinical Trials Database.
- 05 Oct 2018 Status changed from recruiting to discontinued.